Pharmicell

Pharmicell Co., Ltd. is a biopharmaceutical company that develops and sells autologous drugs in South Korea and internationally. It operates through Biopharmaceutical and Biochemical divisions. Its products include Cellgram_AMI, an autologous bone marrow-derived mesenchymal stem cell therapy for acute myocardial infarction, and development-stage candidates such as Cellgram_LC for hepatic insufficiency, Cellgram_ED for impotence, and Hearticellgram_AMI for cardiac disease. The company also produces intermediates for raw material medicines, low dielectric constant materials, eco-friendly flame retardants, polyol synthesis catalysts, and PET catalysts, and provides cell culture media, clinical development and commercialization services, a stem cell bank under the Twelve brand, and stem cell culture media cosmetics. Formerly known as FcB2welve Co., Ltd., it changed its name to Pharmicell Co., Ltd. in September 2011 and was founded in 1968, with headquarters in Seoul, South Korea.